Tucatinib is an oral, highly selective, small-molecule inhibitor of the HER2 tyrosine kinase, used in combination with trastuzumab and capecitabine for the treatment of advanced HER2-positive breast cancer, including those with brain metastases.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea